戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 istant disease (CRPC) when treated with anti-androgen therapy.
2      Thirty-three patients had also received androgen therapy.
3 tations in telomerase genes can improve with androgen therapy.
4 ive androgen receptor modulators (SARMs) for androgen therapy.
5 ese androgen-independent tumors despite anti-androgen therapy.
6 ncer resistance to hormone-ablative and anti-androgen therapy.
7 ese mutations may be the best candidates for androgen therapy.
8  was highest among those receiving exogenous androgen therapy.
9 ontribute to responses to supraphysiological androgen therapy.
10 direct role in preventing resistance to anti-androgen therapy.
11  and restores responsiveness of CRPC to anti-androgen therapy.
12 s, associated genetic factors, or history of androgen therapy.
13 tizing prostate cancer cells to current anti-androgen therapies.
14 apies, ERG promotes sensitivity to high-dose androgen therapy and pharmacological inhibition of wild
15 with zotatifin become more sensitive to anti-androgen therapy and radiotherapy.
16  setting of advanced malignancies, high-dose androgen therapy, and Bartonella henselae infection.
17 e subject of several clinical trials of anti-androgen therapies around the world.
18                                      Bipolar androgen therapy (BAT) - the rapid cycling of supraphysi
19 ivity, which is the basis for use of Bipolar Androgen Therapy (BAT) for patients with this disease.
20                                      Bipolar androgen therapy (BAT) is an emerging treatment for meta
21 physiological androgen (SPA), termed bipolar androgen therapy (BAT), can result in tumor regression a
22                                      Bipolar androgen therapy (BAT), defined as rapid cycling between
23 estosterone administration, known as bipolar androgen therapy (BAT), is a treatment strategy for pati
24  benefits, a strategy that is termed bipolar androgen therapy (BAT).
25 w serum testosterone concentrations (bipolar androgen therapy [BAT]) in this setting might induce tum
26 induced hepatocellular carcinoma (HCC), anti-androgen therapies delay hepatocarcinogenesis.
27  blockade for prostate cancer prevention and androgen therapy for andropause treatment in elderly men
28 roendocrine (NE) cells to escape potent anti-androgen therapies however, the exact molecular events a
29                  However, pharmacologic anti-androgen therapy in advanced HCC patients fails, suggest
30          Our results provide a mechanism for androgen therapy in bone marrow failure: androgens appea
31  findings support the clinical evaluation of androgen therapy in the prevention and perhaps treatment
32 red physical changes from oestrogen and anti-androgen therapy include decreased body and facial hair,
33 drogens led to the development of novel anti-androgen therapies including abiraterone acetate and enz
34 ive activation that is not inhibited by anti-androgen therapies, including abiraterone or enzalutamid
35                                              Androgen therapy is used to compensate for low levels of
36 c stem cell transplantation is critical, and androgen therapy may be helpful.
37  cancers (PCs), initially responsive to anti-androgen therapies, often advance to a hormone-refractor
38 t the majority of patients treated with anti-androgen therapy progress to androgen-independence chara
39  through the transient generation of an anti-androgen therapy-resistant cell population, suggesting t
40 s, such as microRNA and prostate cancer anti-androgen therapy-resistant marker ARV7 splicing variant